Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
Rhea-AI Summary
Intelligent Bio Solutions (Nasdaq: INBS) announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, to deploy INBS’s fingerprint drug screening across 13 UK project sites. Bouygues Construction reported a turnover of €10.3 billion in 2024 and employs 35,600 globally. According to the company, a joint ROI analysis showed substantial cost savings versus third-party testing, and the UK rollout is positioned as a foundation for potential wider expansion across Bouygues operations.
Positive
- 13-site initial commercial deployment in UK project sites
- Joint ROI analysis quantified substantial cost savings versus third-party testing
- Validation of scalability with a global construction account (35,600 employees, €10.3B turnover)
Negative
- Initial deployment limited to 13 sites, constraining near-term revenue expansion
- No contract value or recurring revenue terms disclosed in the announcement
News Market Reaction – INBS
On the day this news was published, INBS declined 2.59%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.3% during that session. Argus tracked a trough of -23.0% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $181K from the company's valuation, bringing the market cap to $7M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While INBS traded down 6.8%, peers showed mixed moves: NXL up 16.71%, AIMD and TRIB down around 3–3.3%, pointing to broader but uneven sector dynamics.
Previous Partnership Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 31 | Manufacturing partnership | Positive | +132.4% | New manufacturing partner to cut costs and expand capacity. |
| Dec 18 | Strategic alliance | Positive | +18.4% | Non-exclusive R&D and distribution alliance for non-invasive testing and wearables. |
| Mar 27 | Regional expansion deal | Positive | -6.6% | Spain/Andorra distributor partnership targeting expanding drug testing markets. |
| Feb 07 | UK expansion deal | Positive | +8.7% | UK freight partnership and disclosure of 400+ accounts across 19 countries. |
| Jan 28 | EU/Middle East deal | Positive | +2.1% | IVY Diagnostics partnership to grow rehabilitation and law enforcement usage. |
Partnership announcements have usually been followed by positive price reactions, with one notable negative divergence.
Over the past year, INBS has repeatedly used partnerships to expand its Intelligent Fingerprinting drug testing footprint. Deals with Syrma Johari MedTech, Vlepis, Detecto, Avon Freight Group, and IVY Diagnostics broadened manufacturing, geographic reach, and applications across Europe, the UK, and the Middle East. These announcements often coincided with strong single‑day moves, including a 132.44% reaction on Dec 31, 2025. Today’s Bouygues UK partnership continues that strategy of scaling via large, multi-site collaborators.
Historical Comparison
Past partnership announcements for INBS averaged a 31.01% one‑day move, with several large spikes, making today’s partnership another data point in a catalyst‑sensitive pattern.
Partnerships show a progression from regional distributors to manufacturing scale-up and now large operational deployments, supporting broader commercialization of the fingerprint drug testing platform.
Regulatory & Risk Context
An effective S-3 resale shelf dated Jan 9, 2026 registers 6,896,550 shares for selling stockholders. INBS would not receive resale proceeds but could receive up to $18.87 million if all registered warrant shares are exercised for cash, and the filing itself flags potential stock price pressure from the large registered block.
Market Pulse Summary
This announcement reinforces INBS’s partnership-driven commercialization strategy, adding a 13-site deployment with Bouygues UK, part of a group with 35,600 employees and €10.3 billion in 2024 turnover. It highlights validation of in-house, fingerprint-based drug testing through joint ROI work and operational benefits. In context of prior manufacturing and distribution alliances, investors may watch for metrics such as additional site rollouts, cartridge volumes, and further multi-country agreements to gauge how this partnership translates into revenue growth.
Key Terms
fingerprint drug testing technology medical
fingerprint drug screening technology medical
return on investment ("ROI") analysis financial
AI-generated analysis. Not financial advice.
Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technology
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi-billion-dollar global construction firm with 35,600 employees, for the deployment of INBS’s fingerprint drug screening technology across its UK operations. The partnership reflects a shift from third-party testing services to an in-house solution, driven by superior hygiene protocols, operational efficiency, and demonstrated cost savings, validated through joint Return on Investment (“ROI”) analysis.
Bouygues Construction operates across more than 50 countries and reported a turnover of
"This partnership demonstrates the commercial viability and operational advantages of our fingerprint drug testing technology with a world-class construction organization," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "Bouygues UK's decision to transition from third-party services to our technology, backed by quantified ROI analysis, validates our value proposition and ability to scale within multinational accounts. We're proud to support Bouygues UK's commitment to workplace safety and operational excellence and view the UK deployment as a foundation for potential expansion across its extended operations."
Bouygues UK’s leadership emphasized the joint nature of the relationship with INBS, distinguishing it as a collaborative partnership rather than a conventional supplier-customer arrangement. Bouygues UK credited the time INBS spent understanding both UK-specific and wider group requirements to ensure effective long-term collaboration.
“Bringing drug testing in-house gives us greater control while improving the process on-site. The fingerprint drug testing approach delivered immediate benefits from a hygiene, employee experience, and testing efficiency perspective, and the subsequent ROI work confirmed it was also the right decision commercially,” said Chris Inwood, Head of Health and Safety at Bouygues UK. “What has stood out throughout this process is the way the team took the time to understand our UK operations within the context of the wider Bouygues group. That level of engagement has enabled a genuine partnership aligned to our safety culture, rather than a traditional supplier agreement.”
The selection followed evaluation of the fingerprint testing approach across multiple aspects, including workplace hygiene, employee well-being, time efficiency, and cost management. An ROI analysis quantified substantial cost savings compared to previous third-party testing arrangements, reinforcing the economic case for the technology in large-scale industrial applications. The decision to transition from external testing services to INBS’s technology demonstrates the platform's operational advantages and cost benefits in demanding, high-stakes construction environments.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://ibs.inc/
About Bouygues UK
Bouygues UK is one of the leading construction companies in the United Kingdom. It focuses on sectors where it can add value through the technical knowledge, skills and experience of its people and the wider global Bouygues group which operates in over 50 countries.
These include:
- Education - schools, colleges, academies, and universities
- Residential - affordable and social housing, private for sale homes, mixed-use, and student accommodation, with a key focus on property development and regeneration
- Healthcare - strategic estate planning, reconfiguration and upgrades, and state-of-the-art, multidisciplinary hospitals
- Science and research - technically complex projects where the company’s specialist skillset can be maximised
- Data centres and distribution.
Building for life and leaving a positive legacy for the next generation is a top priority at Bouygues UK. By incorporating clear carbon guidelines in all its projects, the company works closely with clients, supply chain partners and employees to help reduce its impact on the environment and enable communities to thrive for decades to come. It provides intelligent management throughout the entire life-cycle of each project, delivering efficiently and to an excellent standard, combining a local focus with international strength and expertise. Bouygues UK is wholly owned by Bouygues Construction, a global player in construction and services.
For more information, visit: www.bouygues-uk.com
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
What did Intelligent Bio Solutions (INBS) announce about Bouygues UK on February 24, 2026?
How does the Bouygues UK rollout affect INBS's commercial scalability and growth prospects (INBS)?
What operational benefits did Bouygues UK cite for switching to INBS fingerprint testing (INBS)?
Does the announcement state the financial terms or contract value of the INBS–Bouygues UK agreement?
What is the potential next step after INBS’s initial 13-site deployment with Bouygues UK (INBS)?
